Boehringer, Sosei Heptares partner on schizophrenia treatments

2024-03-11

引进/卖出临床2期临床1期

Boehringer Ingelheim and UK-based Sosei Heptares have entered a global collaboration and option-to-license agreement to develop and commercialize Sosei’s portfolio of GPR52 agonists GPR52 agonists for schizophrenia.

Under the terms of the deal, Boehringer has the exclusive option to license Sosei's GPR52 agonists GPR52 agonists, a novel G protein-coupled receptor target, following the completion of Sosei’s ongoing phase 1 and subsequent phase 1b trial and phase 2 enabling activities with HTL0048149, a first-in-class GPR52 agonist GPR52 agonist. Sosei Heptares will sponsor the trials until the option exercise, estimated in 2025.

According to Boehringer, the development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia — ‘positive’ symptoms (psychosis, delusions and hallucinations), ‘negative’ symptoms (social withdrawal and apathy) and cognitive symptoms (attention, planning and memory deficits).

In the deal, Sosei will receive an upfront payment of $27.3 million (€25 million) from Boehringer, and is eligible for an option exercise payment of $65.6 million (€60 million) and further development, regulatory and commercialization milestone payments totaling up to $732.7 million (€670 million).

Boehringer Ingelheim has inked several deals since the start of 2024. In January, the German drugmaker signed at $2 billion+ deal with Suzhou Ribo Life Science subsidiary Ribocure Pharmaceuticals to develop treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This was quickly followed by a second research partnership with 3T Biosciences — this time for $538.5 million — to develop first-in-class immuno-oncology treatments.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构